Cargando…

Alleviation of Metabolic Endotoxemia by Milk Fat Globule Membrane: Rationale, Design, and Methods of a Double-Blind, Randomized, Controlled, Crossover Dietary Intervention in Adults with Metabolic Syndrome

BACKGROUND: Milk fat globule membrane (MFGM) is a phospholipid-rich component of dairy fat that might explain the benefits of full-fat dairy products on cardiometabolic risk. Preclinical studies support that MFGM decreases gut permeability, which could attenuate gut-derived endotoxin translocation a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quarles, William R, Pokala, Avi, Shaw, Emily L, Ortega-Anaya, Joana, Hillmann, Lisa, Jimenez-Flores, Rafael, Bruno, Richard S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Research Methodology/Study Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456308/ https://www.ncbi.nlm.nih.gov/pubmed/32885133 http://dx.doi.org/10.1093/cdn/nzaa130

Ejemplares similares

Milk-Fat-Globule-Membrane-Enriched Dairy Milk Compared with a Soy-Lecithin-Enriched Beverage Did Not Adversely Affect Endotoxemia or Biomarkers of Gut Barrier Function and Cardiometabolic Risk in Adults with Metabolic Syndrome: A Randomized Controlled Crossover Trial
por: Pokala, Avinash, et al.
Publicado: (2023)

Improving Human Health with Milk Fat Globule Membrane, Lactic Acid Bacteria, and Bifidobacteria
por: Kosmerl, Erica, et al.
Publicado: (2021)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

Rationale and design of the EMPYREAN study
por: Motoki, Hirohiko, et al.
Publicado: (2020)

Rationale and design of the AUGUST‐AHF Study
por: Zhang, Jingjing, et al.
Publicado: (2020)

Mechanisms of Diuretic Resistance Study: design and rationale
por: Cox, Zachary L., et al.
Publicado: (2020)

Rationale and Design of the PRegnancy and Infant DEvelopment (PRIDE) Study
por: van Gelder, Marleen M H J, et al.
Publicado: (2013)

The genomics of heart failure: design and rationale of the HERMES consortium
por: Lumbers, R. Thomas, et al.
Publicado: (2021)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

Rate or Rhythm Control in CRT (RHYTHMIC): Study rationale and protocol
por: Elliott, Mark K., et al.
Publicado: (2022)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
por: Farrant, John, et al.
Publicado: (2023)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST
por: Cowie, Martin R., et al.
Publicado: (2020)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
por: Tajstra, Mateusz, et al.
Publicado: (2023)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
por: Dauw, Jeroen, et al.
Publicado: (2021)

Impact of the Pandemic on NonInfected Cardiometabolic Patients: A Survey in Countries of Latin America—Rationale and Design of the CorCOVID LATAM Study
por: Lopez Santi, Ricardo, et al.
Publicado: (2020)

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
por: Palazzuoli, Alberto, et al.
Publicado: (2017)

Rationale and design of the EU‐CERT‐ICD prospective study: comparative effectiveness of prophylactic ICD implantation
por: Zabel, Markus, et al.
Publicado: (2018)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure
por: Krzesiński, Paweł, et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial
por: Keene, Daniel, et al.
Publicado: (2018)

Rationale and design for ENHANCE CRT: QLV implant strategy for non‐left bundle branch block patients
por: Singh, Jagmeet P., et al.
Publicado: (2018)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
por: Scheffer, Mariëlle, et al.
Publicado: (2020)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Electrographic flow–guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale
por: Szili-Torok, Tamas, et al.
Publicado: (2023)

Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study
por: Correale, Michele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9e8i417169583schup4jm0798j